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SUPPLEMENTARY METHODS: 
Cell proliferation assay: 
10,000 cells/well of a 12-well plate were seeded in duplicate for each of five days. Cells were trypsinized 
and counted by hemocytometer. Doubling times were calculated from an exponential growth curve using 
GraphPad Prism (v5.0).  
Measurement of cholesterol and lipids: 
1,000,000 cells were seeded overnight on 10 cm plates and treated with ethanol vehicle control, 10 µM 
fluvastatin or serum withdrawal to 0.01% FBS for 16 h. Cells were washed with PBS, harvested on ice in 
1.5 ml ice-cold PBS supplemented with “cOmplete” protease inhibitor cocktail (Roche) and processed 
similarly to our previous report [1]. Cells were sonicated, phospholipid polar heads were removed by 
incubation with Phospholipase C, and total lipids were extracted in Folch solution (chloroform:methanol, 
2:1, [v/v]). Lipids were derivatized and analyzed on an Agilent 6890 gas chromatographer with a flame-
ionization detector and a Zebron ZB-5 column (Phenomenex; 30 m x 0.32 mm I.D. x 0.25 μm film 
thickness). Results were analyzed with Agilent Chemstation software and corrected to a 2 µg tridecanoin 
internal standard added during lipid extraction. 
Data mining for fluvastatin sensitivity-associated gene expression: 
Publicly available microarray data for 51 breast cancer cell lines [2] were preprocessed using updated cdf 
files that map probes to Entrez Gene IDs (hgu133ahsentrezgcdf; v15.0.0) and the RMA algorithm [3] as 
implemented in the affy package (v1.32.1) for R (v2.14.2). Of the cell lines used in this report, HCC1806, 
SW527 and HCC1419 were not represented in this dataset. A Y chromosome filtration was applied to 
remove unexpressed genes according to background hybridization levels [4]. Genes with intensities below 
5.0 in all cell lines were excluded from downstream analyses. An analysis of Gene Ontology (GO) term 
enrichment was performed on the dataset of fluvastatin sensitivity-associated genes using the web-based, 
high-throughput version of GOMiner (Build 291) [5]. All GO terms were evaluated in human-specific 
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databases, and statistical constraints for summary reports were set to 0.1. One thousand randomizations 
were utilized. 
Verification of mRNA abundance correlations with NanoString technology: 
Forty-eight samples (23 cell lines in duplicate, 2 cell lines as single samples) were processed on the 
NanoString platform to detect the mRNA abundance of 25 genes, according to standard protocols at the 
University Health Network Microarray Centre (Toronto, Canada). NanoString data was preprocessed 
using the NanoStringNorm (v1.1.11) package for R (v2.15.2) [6]. The geometric mean was used to 
normalize for technical assay variation while the background count level was estimated using the 
maximum of the negative controls. Finally, RNA content was normalized using the geometric mean of 
three housekeeping genes, glucuronidase, beta (GUSB), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and hypoxanthine phosphoribosyltransferase 1 (HPRT1). One replicate of HS578T was 
removed from the data processing due to positive normalization outside of the acceptable range. For 
sample replicates, the mean for each gene was calculated and utilized for downstream analysis. 
Affymetrix data was processed as noted above. Affymetrix expression levels for the 25 genes from the 
samples evaluated on NanoString were isolated to create a comparable dataset. Spearman correlation 
coefficients between the NanoString and Affymetrix expression data were calculated. Both datasets were 
also independently correlated to the mean fluvastatin MTT50 of each cell line, calculating Pearson 
correlation coefficients. Samples were then compared using the diana clustering algorithm found in the 
cluster package (v1.14.3) for R.(v2.15.2). All visualizations were created using the lattice (v0.20-10) and 
latticeExtra (v1.26.0) packages in R (v2.15.2). 
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Supplementary Figure S1. Fluvastatin sensitivity does not appear to be solely associated with proliferative rate 
in a subpanel of breast cell lines. Subconfluent cells were seeded in duplicate and counted in duplicate over five days 
by hemocytometer. Doubling times were calculated from exponential growth curves. Bars represent mean doubling 
times from three independent experiments, with error bars indicating standard deviation. 
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Supplementary Figure S2. Representative TUNEL vs. PI dotplots from additional cell lines demonstrating 
differential induction of apoptosis following fluvastatin treatment. The proportion of cells undergoing apoptosis 
following treatment with fluvastatin or ethanol vehicle control for 72 h was determined by TUNEL staining and flow 
cytometric detection. Numbers highlighted in the upper right corners of each dotplot represent the number of events 
detected in the TUNEL-positive gate shown. Experiments were repeated three times. 
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Supplementary Figure S3. HMGCR regulation and lipid pools are similar 
in cell lines with differing fluvastatin sensitivity. A. HMGCR-FL mRNA 
levels induced by treatment with 10 µM fluvastatin, relative to GAPDH, were 
assessed by RT-PCR and normalized relative to ethanol vehicle control levels, 
highlighted by the gray line at 1. Bars represent means of three to five 
independent experiments, with error bars indicating standard deviation. 
Asterisks denote a statistically significant difference from 1 by a one-sample t-
test (p < 0.05). B. Total HMGCR protein levels following treatment with 10 μM 
fluvastatin or ethanol vehicle control for 24 h were assessed by SDS-PAGE 
and immunoblotting for HMGCR with the A9 monoclonal antibody, with actin 
as a loading control. Identical negative and positive HMGCR control lysates 
were loaded on each gel. The negative control (“Neg. ctrl”) lysate was from the 
HMGCR-deficient UT2 cell line ectopically expressing a control vector, and the 
positive control lysate was from the UT2 cell line ectopically expressing 
HMGCR-FL (“Pos. ctrl.”; CA Goard and LZ Penn, unpublished data). 
Immunoblots shown are representative of three independent experiments. C. 
Baseline lipid levels in a subpanel of cell lines were assessed by gas 
chromatography, expressed as the amount of analyte relative to total protein 
content. Bars represent means of two to three independent experiments, with 
error bars indicating standard deviation. 
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Supplementary Figure S4. mRNA abundance of a subset of 
genes is similar mined Affymetrix array data and NanoString 
detection. Baseline mRNA levels of 25 genes were assessed in 
a panel of 25 breast cell lines and compared to mRNA 
abundance in these cell lines as determined by mining publicly 
available Affymetrix array-based data. A. Hierarchical Diana 
clustering confirms that duplicate samples of cell lines are most 
similar to each other in mRNA abundance patterns, with the 
exception of one cell line (MDAMB231). Heatmap displays 
normalized mRNA abundance values. B. A comparison of the 
correlations between mRNA abundance of each gene determined 
by either Affymetrix array data or NanoString verification and 
fluvastatin MTT50 demonstrates that similar correlations are 
detected for most genes. Yellow data points indicate the 10 
genes comprising the gene signature while the black data points 
represent the remaining genes processed on NanoString. The 
Spearman correlation coefficient, ρ, and its associated p-value 
demonstrate a strong concordance between associations of 
mRNA abundance detected by either method with fluvastatin 
sensitivity. 
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